- Home
- NXL vs PRPH Comparison
NXL vs PRPH Comparison
Compare NXL & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- PRPH
- Stock Information
- Founded
- NXL 2010
- PRPH 1989
- Country
- NXL United States
- PRPH United States
- Employees
- NXL N/A
- PRPH N/A
- Industry
- NXL Medical Specialities
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- NXL Health Care
- PRPH Health Care
- Exchange
- NXL Nasdaq
- PRPH Nasdaq
- Market Cap
- NXL 21.0M
- PRPH 17.7M
- IPO Year
- NXL 2022
- PRPH 1997
- Fundamental
- Price
- NXL $0.89
- PRPH $0.28
- Analyst Decision
- NXL Strong Buy
- PRPH
- Analyst Count
- NXL 1
- PRPH 0
- Target Price
- NXL $5.00
- PRPH N/A
- AVG Volume (30 Days)
- NXL 123.3K
- PRPH 1.1M
- Earning Date
- NXL 08-06-2025
- PRPH 08-13-2025
- Dividend Yield
- NXL N/A
- PRPH N/A
- EPS Growth
- NXL N/A
- PRPH N/A
- EPS
- NXL N/A
- PRPH N/A
- Revenue
- NXL $174,813.00
- PRPH $5,845,000.00
- Revenue This Year
- NXL $79.59
- PRPH $221.82
- Revenue Next Year
- NXL $334.65
- PRPH N/A
- P/E Ratio
- NXL N/A
- PRPH N/A
- Revenue Growth
- NXL 16.42
- PRPH N/A
- 52 Week Low
- NXL $0.59
- PRPH $0.22
- 52 Week High
- NXL $4.49
- PRPH $3.00
- Technical
- Relative Strength Index (RSI)
- NXL 33.31
- PRPH 35.31
- Support Level
- NXL $0.86
- PRPH $0.30
- Resistance Level
- NXL $1.10
- PRPH $0.35
- Average True Range (ATR)
- NXL 0.09
- PRPH 0.04
- MACD
- NXL -0.02
- PRPH -0.01
- Stochastic Oscillator
- NXL 7.30
- PRPH 1.93
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.